ArticleFrontiers in surgery2026
Axillary response and diagnostic accuracy of imaging modalities after neoadjuvant chemotherapy for breast cancer (retrospective single center study).
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The optimal axillary approach after neoadjuvant chemotherapy (NACT) in patients with breast cancer (BC) remains controversial. In our study, we aimed to evaluate factors affecting axillary pathological complete response (pCR) in patients with biopsy-proven node-positive BC before NACT and to assess the diagnostic performance of imaging modalities in detecting residual axillary metastasis after NACT. Methods: Our sample included 142 patients with T1-3, N1-2, M0 BC who were cytologically confirmed to have axillary metastasis by ultrasonography (USG), mammography (MG), magnetic resonance imaging (MRI), and 18F-FDG positron emission tomography-computed tomography (PET-CT) and who received NACT between 2020 and 2025. Patients showing clinical or radiologic complete response in the axilla underwent sentinel lymph node biopsy (SLNB). SLNB-positive patients subsequently underwent level I-II axillary dissection (AD). Pathological, molecular, and imaging findings of the patients were analyzed. Results: After NACT, 78 patients (54.9%) had no residual axillary metastasis. HER2 positivity and progesterone receptor (PR) negativity were significantly associated with axillary pCR (p < 0.05). Luminal A and B tumors demonstrated lower response rates to NACT, whereas HER2-rich and triple-negative subtypes showed higher axillary pCR rates (85.7% and 71.4%, respectively). Among imaging modalities, the specificity values were 91.2% and 84.6% for PET-CT and USG, respectively. Negative predictive values (NPV) were 74.02% and 76.52% for PET-CT and USG, respectively. Discussion and conclusion: In PR-positive and HER2-negative tumors, the likelihood of axillary pCR is lower, and careful evaluation is warranted. USG and PET-CT may serve as a good guide for axillary lymph node assessment after NACT in patients with BC. However, given their modest sensitivity, imaging modalities should be considered complementary tools rather than substitutes for pathological axillary staging. Further prospective randomized trials are needed to define patient groups who may safely avoid axillary dissection after NACT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.